These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 3560192)

  • 21. A simple one-step hemolytic assay for C2 with C2-deficient human serum.
    Ngan BY; Gelfand EW; Minta JO
    J Immunol; 1977 Mar; 118(3):736-41. PubMed ID: 321681
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stoichiometry and sedimentation properties of the complex formed between the C1q and C1r2C1s2 subcomponents of the first component of complement.
    Siegel RC; Schumaker VN; Poon PH
    J Immunol; 1981 Dec; 127(6):2447-52. PubMed ID: 6975324
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Threshold mechanism of the control of cascade proteolysis].
    Shcherbak IG
    Bioorg Khim; 1998 May; 24(5):364-9. PubMed ID: 9661790
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of aggregate size on the binding and activation of the first component of human complement by soluble IgG aggregates.
    Doekes G; Vanes LA; Daha MR
    Immunology; 1982 Apr; 45(4):705-13. PubMed ID: 7068172
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevention of immune precipitation by purified classical pathway complement components.
    Naama JK; Hamilton AO; Yeung-Laiwah AC; Whaley K
    Clin Exp Immunol; 1984 Nov; 58(2):486-92. PubMed ID: 6333948
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process.
    Hamad I; Hunter AC; Szebeni J; Moghimi SM
    Mol Immunol; 2008 Dec; 46(2):225-32. PubMed ID: 18849076
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The relationship between the binding ability and the rate of activation of the complement component C1.
    Folkerd EJ; Gardner B; Hughes-Jones NC
    Immunology; 1980 Sep; 41(1):179-85. PubMed ID: 7429549
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mechanisms of complement activation and effects of C1-inhibitor on the meconium-induced inflammatory reaction in human cord blood.
    Salvesen B; Nielsen EW; Harboe M; Saugstad OD; Mollnes TE
    Mol Immunol; 2009 Feb; 46(4):688-94. PubMed ID: 18950866
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The enhancement of the haemolytic activity of the first component of complement by trasylol.
    Delage JM; Simard J; Lehner-netsch G
    Immunology; 1976 Oct; 31(4):601-6. PubMed ID: 1086286
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A rapid and simple assay to determine if macroamylase is the cause of hyperamylasemia.
    Levitt MD; Ellis C
    Gastroenterology; 1982 Aug; 83(2):378-82. PubMed ID: 6177576
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activation of first component of complement (C1) in guinea pig serum by a polysaccharide is prevented by C1 inhibitor.
    Schultz DR; Arnold PI
    J Immunol; 1981 Apr; 126(4):1558-61. PubMed ID: 7204976
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Secreted chondroitin sulfate proteoglycan of human B cell lines binds to the complement protein C1q and inhibits complex formation of C1.
    Kirschfink M; Blase L; Engelmann S; Schwartz-Albiez R
    J Immunol; 1997 Feb; 158(3):1324-31. PubMed ID: 9013976
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Studies on the haemolytic activity of circulating C1q-C3/C4 complexes.
    Wouters D; Brouwer MC; Daha MR; Hack CE
    Mol Immunol; 2008 Apr; 45(7):1893-9. PubMed ID: 18054386
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of plicatic acid on human serum complement includes interference with C1 inhibitor function.
    Giclas PC
    J Immunol; 1982 Jul; 129(1):168-72. PubMed ID: 6979566
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Physicochemical and pharmacokinetic characterization of highly potent recombinant L-methionine gamma-lyase conjugated with polyethylene glycol as an antitumor agent.
    Takakura T; Takimoto A; Notsu Y; Yoshida H; Ito T; Nagatome H; Ohno M; Kobayashi Y; Yoshioka T; Inagaki K; Yagi S; Hoffman RM; Esaki N
    Cancer Res; 2006 Mar; 66(5):2807-14. PubMed ID: 16510603
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of liposome-induced complement activation by incorporated poly(ethylene glycol)-lipids.
    Bradley AJ; Devine DV; Ansell SM; Janzen J; Brooks DE
    Arch Biochem Biophys; 1998 Sep; 357(2):185-94. PubMed ID: 9735159
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Specific, sensitive, precise, and rapid functional chromogenic assay of activated first complement component (C1) in plasma.
    Munkvad S; Jespersen J; Sidelmann J; Gram J
    Clin Chem; 1990 Jul; 36(7):1305-11. PubMed ID: 2372942
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Complement activation, circulating C1q binding substances and inflammatory activity in rheumatoid arthritis: relations and changes on suppression of inflammation.
    Berglund K; Laurell AB; Nived O; Sjoholm AG; Sturfelt G
    J Clin Lab Immunol; 1980 Jul; 4(1):7-14. PubMed ID: 7463476
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Complement activation on surfaces modified with ethylene glycol units.
    Arima Y; Toda M; Iwata H
    Biomaterials; 2008 Feb; 29(5):551-60. PubMed ID: 17981322
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A colorimetric assay for estimation of polyethylene glycol and polyethylene glycolated protein using ammonium ferrothiocyanate.
    Nag A; Mitra G; Ghosh PC
    Anal Biochem; 1996 Jun; 237(2):224-31. PubMed ID: 8660570
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.